SCHEMBL3186402

SCHEMBL3186402

CC1(c2ccc(Br)cn2)CO1

nearest known ligand 0.36

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.36
GBA1 P04062 1/20 0.35
TAAR1 Q96RJ0 1/20 0.34
KDM4E B2RXH2 1/20 0.33
TSHR P16473 2/20 0.33
NPSR1 Q6W5P4 1/20 0.33
LMNA P02545 1/20 0.33
HPGD P15428 1/20 0.33
MAPK1 P28482 1/20 0.33
HTT P42858 1/20 0.33
BACE1 P56817 2/20 0.32
BACE2 Q9Y5Z0 2/20 0.32
POLB P06746 1/20 0.32
ADRA2A P08913 2/20 0.32
ADRA2B P18089 2/20 0.32
ADRA2C P18825 2/20 0.32
PLAU P00749 1/20 0.32
RAB9A P51151 1/20 0.31
FDPS P14324 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12951877 0.79 ALDH1A1 (0.35) ALDH1A1GBA1TAAR1KDM4ETSHR
SCHEMBL14946800 0.76 ALDH1A1 (0.39) ALDH1A1GBA1KDM4ETSHRNPSR1
SCHEMBL19061363 0.72 GBA1 (0.34) ALDH1A1GBA1KDM4ETSHRNPSR1
SCHEMBL15612499 0.72 TSHR (0.36) ALDH1A1KDM4ETSHRNPSR1LMNA
SCHEMBL15248282 0.72 TSHR (0.33) ALDH1A1GBA1KDM4ETSHRLMNA
SCHEMBL15611846 0.72 TSHR (0.33) ALDH1A1GBA1KDM4ETSHRNPSR1
SCHEMBL17316447 0.72 ATM (0.33) ALDH1A1GBA1KDM4ETSHRLMNA
SCHEMBL34472699 0.72 BACE1 (0.34) ALDH1A1GBA1KDM4ETSHRLMNA
SCHEMBL2653656 0.71 ALDH1A1 (0.36) ALDH1A1GBA1KDM4ETSHRNPSR1
Hydrochloric Acid SCHEMBL15240828 0.70 ADRA2A (0.36) ALDH1A1GBA1KDM4ETSHRLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101965353-B Bicyclic nitroimidazoles covalently linked to substituted phenyl oxazolidinones TENNOR THERAPEUTICS SUZHOU CO LTD 2014-12-17 CN disclosed
EP-2254892-B1 BICYCLIC NITROIMIDAZOLES COVALENTLY LINKED TO SUBSTITUTED PHENYL OXAZOLIDINONES GLOBAL ALLIANCE FOR TB DRUG DEV (US) 2014-04-23 EP disclosed
EP-2254892-B1 BICYCLIC NITROIMIDAZOLES COVALENTLY LINKED TO SUBSTITUTED PHENYL OXAZOLIDINONES GLOBAL ALLIANCE FOR TB DRUG DEV (US) 2014-04-23 EP disclosed
CN-101965353-A Covalently bound dicyclo nitro glyoxaline to the substituted benzene oxazolidinone GLOBAL ALLIANCE FOR TB DRUG DEV 2011-02-02 CN disclosed
EP-2254892-A1 BICYCLIC NITROIMIDAZOLES COVALENTLY LINKED TO SUBSTITUTED PHENYL OXAZOLIDINONES Global Alliance For Tb Drug Development (US) 2010-12-01 EP disclosed
US-7666864-B2 Bicyclic nitroimidazole-substituted phenyl oxazolidinones GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT (US) 2010-02-23 US disclosed
US-7666864-B2 Bicyclic nitroimidazole-substituted phenyl oxazolidinones GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT (US) 2010-02-23 US disclosed
US-20090281088-A1 BICYCLIC NITROIMIDAZOLE-SUBSTITUTED PHENYL OXAZOLIDINONES GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT (US) 2009-11-12 US disclosed
US-20090281088-A1 BICYCLIC NITROIMIDAZOLE-SUBSTITUTED PHENYL OXAZOLIDINONES GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT (US) 2009-11-12 US disclosed
WO-2009120789-A1 BICYCLIC NITROIMIDAZOLES COVALENTLY LINKED TO SUBSTITUTED PHENYL OXAZOLIDINONES GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT (US) 2009-10-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090281088-A1 BICYCLIC NITROIMIDAZOLE-SUBSTITUTED PHENYL OXAZOLIDINONES O60361, OXA1L, TBCD ALDH1A1 2303/4885GBA1 4146/4885TAAR1 3619/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.